COPD Flashcards
Risk Factors for COPD
Age and gender (female) Chemical exposure (smoke, etc) Genetic (alpha-1-antitrypsin def) Socioeconomic status Chronic lung diagnostics (asthma or chronic bronchitis
Emphysema Clinical Presentation
o Severe dyspnea (SOB)
o Cough AFTER dyspnea
o Sputum- scanty and mucoid
Bronchitis Clinical Presentation
o Less severe dyspnea
o Cough BEFORE dyspnea
o Sputum- copious and purulent
4 Steps to Assess COPD
o Symptom severity → spirometry → exacerbation → comorbidities (smoking, HF, etc)
3 Most Common Symptoms of COPD
Dyspnea (progressive and persistent or exertional breathlessness)
Chronic cough
Chronic sputum productions
COPD Assessment Test (CAT)
o Less than 10 = low
o 10-20 = moderate
o 20-30 = high
o >30 = very high
In patients with… you can use COPD spirometric Grading
FEV1/FVC less than 0.70
GOLD 1 =
Mild
FEV1 >/= 80% predicted
GOLD 2 =
Moderate
50%-80% FEV1 predicted
GOLD 3 =
Severe
30%-50% of FEV1 predicted
GOLD 4 =
Very severe
Less than 30% predicted FEV1
Category A =
mMRC 0-1 CAT less than 10 \+ GOLD 1 or 2 Exacerbation 0-1
Category B =
mMRC >/=2 CAT >/= 10 \+ GOLD 1 or 2 Exacerbation 0-1
Category D =
mMRC >/= 2
CAT >/= 10
+
Category C =
mMRC >/=2 CAT >/= 10 \+ GOLD 3 or 4 Exacerbation 2+
Non-Pharmacologic Recommendations for COPD
Smoking Cessation
Pulmonary Rehab
Immunizations
What Immunizations?
Influenza Pneumonia (Per ACIP COPD is a qualifying condition to receive PPSV23 prior to age 65; ACIP recommends PCV14 at 65 years then PPSV23 1 year later and 5 years after the first dose of PPSV23)
Short Acting Beta 2 Agonists
Albuterol
Combivent (albuterol + ipratropium)
Duoneb (albuterol + ipratropim nebs)
Long Acting Beta 2 Agonists
Salmetrol Formoterol Advair (salmeterol + fluticasone) Symbicort (budesinide + formoterol) Dulera (mometasone + formoterol)
Beta 2 Agonists MOA
Bronchodilation, smooth muscle relaxation